This article dissects Montagu Private Equity's ambitious rollup of three orthopedic device companies, comparing it to their proven Nemera playbook, to reveal strategic synergies, growth prospects, and risks that could shape the future of medical innovation and investor returns.
Let's jump in.
Montagu Private Equity, leveraging its established carve-out and rollup expertise from deals like Nemera's drug delivery platform, is now applying a similar playbook to the orthopedic device sector. Historically, Montagu has excelled in healthcare investments, completing over 30 carve-outs since 2002, in...
